Biological agents: a novel approach to the therapy of rheumatoid arthritis (Q34074934)

30 July 2017

1 reference

title

Biological agents: a novel approach to the therapy of rheumatoid arthritis (English)

1 reference

30 July 2017

1 reference

Lorenz HM

1

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 July 2000

1 reference

Expert Opinion on Investigational Drugs

30 July 2017

published in

1 reference

30 July 2017

volume

9

1 reference

30 July 2017

issue

7

1 reference

30 July 2017

page(s)

1479-1490

1 reference

Rheumatoid arthritis. Pathophysiology and implications for therapy

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1479

Long-term second-line treatment: a prospective drug survival study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1479

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1479

Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1479

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1479

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1479

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1479

The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1479

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1479

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1479

Specificity of a porcine 127-kd nucleotide pyrophosphohydrolase for articular tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1479

Interleukin-4 and interleukin-10 are chondroprotective and decrease mononuclear cell recruitment in human rheumatoid synovium in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.7.1479

10.1517/13543784.9.7.1479

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference